ESPR — Esperion Therapeutics Share News
0.000.00%
Last trade - 00:00- $822.04m
- $1.21bn
- $403.14m
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi
Brief: BioPharma Credit Says Co's Allocation Of Financing Of Esperion Deal Between $78 Million And $120 Million
U.S. RESEARCH ROUNDUP- Alphabet, Colgate-Palmolive, Welltower
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Perella Weinberg Partners, Amkor Technology, Esperion Therapeutics
Brief: Essence To Pay Esperion $68.3 Mln Termination Fee If Merger Not Consummated
U.S. STOCKS ON THE MOVE-Paramount Skydance, Newell Brands, Rhythm,
U.S. STOCKS ON THE MOVE-Zetta Global, Church & Dwight
Esperion Therapeutics surges on Archimed's $1.1 bln go-private deal
Archimed to take Esperion Therapeutics private in $1.1 billion deal (updated)
NASDAQ RESUMED AT 07:25 AM
Archimed to take Esperion Therapeutics private for up to $1.1 billion
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Athyrium Capital Management And Esperion Enter Into $50 Million Japan Royalty Financing To Support Strategic Acquisition Of Corstasis Therapeutics
Brief: Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026 - SEC Filing
Brief: Esperion Therapeutics Closes Acquisition Of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)